首页 | 本学科首页   官方微博 | 高级检索  
检索        

如何干预精神病风险综合征?(英文)
引用本文:王继军,江开达,张天宏,Huijun LI,Kristen WOODBERRY,Larry SEIDMAN.如何干预精神病风险综合征?(英文)[J].上海精神医学,2013,25(1):6-9.
作者姓名:王继军  江开达  张天宏  Huijun LI  Kristen WOODBERRY  Larry SEIDMAN
作者单位:Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine;Department of Psychology, Florida A & M University,Tallahassee, FL, United States;Department of Psychiatry, Harvard Medical School Beth Israel Deaconess Medical Center,Boston, MA , United States
基金项目:supported by grants from the following agencies:NIMH R21 (1R21MH093294-01A1);National Natural Science Foundation of China (NSFC-NIH) (81261120410);NSFC (81171267, 81201043);Shanghai Science and Technology Committee (11410708800, 10411966400);National Key Clinical Disciplines at Shanghai Mental Health Center (OMA-MH, 2011-873)
摘    要:Research diagnostic instruments such as the Structured Interview for Prodromal Syndromes (SIPS) are now able to reliably identify individuals with different types of psychosis risk syndromes (PRS). About one-third of individuals with PRS convert to a diagnosable psychotic disorder within three years of the initial assessment. Currently available randomized controlled trials of interventions aimed at reducing the rate of psychotic conversion of PRS are promising, but they are too small and too short in duration to provide definitive conclusions about effectiveness. Given the high level of false positives (i.e., most individuals with PRS do not progress to frank psychosis) and the lack of definitive evidence about effectiveness, we recommend a staged approach to intervention in PRS that only uses antipsychotic medication after other, more benign approaches have been tried. At present the best approach appears to be to develop high-quality case- management systems for individuals with PRS that provide close follow-up, psychoeducation and psychosocial support to patients and family members, and, possibly, psychotherapeutic and pharmacological treatments (with antipsychotic medications or neuroprotective agents). The effectiveness of these proposed interventions needs to be tested in large randomized controlled trials that follow up subjects for at least three years.

本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号